June 25, 2025 -- DIMERx, Inc., a late-stage biopharmaceutical company entering growth phase, today announced it has been awarded a UG3/UH3 cooperative agreement (UG3DA061645) for up to $15 million from the National Institute on Drug Abuse (NIDA) to advance its lead drug candidate, DMX-101, as a non-addictive oral therapy for chronic lower back pain. The grant was awarded through the NIH Helping to End Addiction Long-term® Initiative, a trans-agency effort aimed at speeding solutions to the op

Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program Funding to support MOCART, a clinical programme evaluating mocravimod added to standard CAR-T cell therapy 24 June 2025– Priothera, a late-stage biopharma company pioneering the development of mocravimod, a novel oral sphingosine 1 phosphate (S1P) receptor modulator, to treat hematologic malignancies, today announced that it has been awarded nearly €1.7 million in non-dilutive funding through the i-

Proceeds to fund Phase 1/2 trial of EO2463 OncoMimics™, as a monotherapy or in combination, to treat multiple forms of indolent non-Hodgkin lymphoma (iNHL) $9 million from new investor The Institute for Follicular Lymphoma Innovation (IFLI) $10 million from existing specialist investors, including The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) June 12, 2025 Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has r

Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. June 04, 2025 -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has entered a $10 million senior secured promissory note (the “Note”) with existing investor, GKCC, LLC (“Note Holder” or “GKCC”) (the “Note Financing”

June 02, 2025 -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced it has been awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). The grant will support development of MiNK’s allo-iNKT cell therapy platform for the prevention and treatment of graft-versus-host disease (GvHD)

May 15, 2025 -- Pathos AI, a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D financing, bringing its post-money valuation to approximately $1.6 billion. This financing marks a major milestone for Pathos as it expands its AI-enabled platform to drive greater speed, precision, and success in oncology drug development. The proceeds will support advancement of the company’s clinical-stage pipeline and c

Financing includes participation from Schooner Capital, Alexandria Venture Investments, and other existing investors Investment accelerates advancement of RPT1G, a novel NAMPT inhibitor, into a Phase 1/2 trial in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) Phase 1 clinical study of RPT1G in healthy volunteers concludes in May 2025 May 13, 2025 -- Remedy Plan Therapeutics (Remedy Plan), a privately-held, clinical-stage pharmaceutical company developi

May 08, 2025 -- OrganOx Ltd., a leading organ medical technology company, completed a second closing of its private placement with investments from Intuitive Ventures, Terumo Ventures, and Piper Heartland Healthcare LLC. Together with the first closing of its private placement on February 24, 2025, OrganOx raised $160 million in primary and secondary equity financing to accelerate growth opportunities for its metra® platform technology in the large and high growth organ technology global market

Completed seed financing round of $7 million from an institutional investor and ImmuneWalk’s management team Includes oral presentation of positive safety, pharmacokinetic, and pharmacodynamic data from immunology and inflammation (I&I) candidate IW-601’s Phase 1 single ascending dose study May 07, 2025 -- ImmuneWalk Therapeutics, a clinical stage company focused on modulating immune and inflammatory disease through monocyte inhibition, today announced the completion of a $7 million seed fina

Angelini Ventures marks its first investment in the cardiovascular and gene therapy space – and first in Asia, further diversifying its strong and growing portfolio 6 May 2025 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and Digital Health, today announces that it has co-led a $45 million Series B financing round in Nuevocor, an IND-stage biotechnology company specialized in the development of